lenalidomide has been researched along with Cell Transformation, Neoplastic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bustany, S; Cahu, J; Colomer, D; Martínez, A; Moros, A; Roué, G; Saborit-Villarroya, I; Sola, B | 1 |
| Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T | 1 |
| Schleiffenbaum, BE | 1 |
| Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Alimena, G; Barzotti, R; Breccia, M; Cannella, L; Ferretti, A; Latagliata, R; Loglisci, G; Nanni, M; Oliva, EN; Santopietro, M | 1 |
| Espinal-Witter, R; Geyer, JT; Knowles, DM; Mathew, S; Orazi, A; Racchumi, J; Subramaniyam, S; Verma, S; Wang, YL | 1 |
| Santini, V | 1 |
2 review(s) available for lenalidomide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic | 2014 |
Novel therapeutic strategies: hypomethylating agents and beyond.
Topics: Aged; Aged, 80 and over; Algorithms; Cell Transformation, Neoplastic; Comorbidity; Cytogenetics; DNA Methylation; Erythropoiesis; Hematology; Humans; Immunosuppressive Agents; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Remission Induction; Thalidomide; Treatment Outcome | 2012 |
6 other study(ies) available for lenalidomide and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Female; Gene Expression; Heterografts; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Protein Binding; Protein Stability; Thalidomide; Tumor Burden | 2014 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Thalidomide | 2016 |
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
Topics: Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis | 2017 |
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Spectral Karyotyping; Thalidomide | 2011 |
Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Janus Kinase 2; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Sequence Deletion; Thalidomide | 2013 |